Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering – Page 4

Silicon Valley elites are quietly appointing themselves ancestors of the future.

As American fertility rates continue to hit record lows — well below the “replacement rate” from one generation to the next — the pronatalism movement has found a foothold in the tech world.

Elon Musk — who apparently now has 13 children — has openly endorsed the movement, which believes in pumping out babies to fight societal collapse. OpenAI CEO Sam Altman has said, “Of course I’m going to have a big family” and is investing in experimental fertility technology.

Read more | >

Bryan Johnson took ketamine and monitored his brain activity for 15 days, recording the experience and sharing about it on X.

Johnson is a 47-year-old longevity-obsessed entrepreneur, known for sharing biohacking content across his social media channels. His most recent health experiment involved treatment with the popularized horse tranquilizer.

As he shared in a tweet, he wanted to test what happens to the brain before, during, and after ketamine treatment.

Ketamine has gained popularity as a fast-acting treatment for depression, PTSD, and chronic pain. Unlike traditional antidepressants, it works quickly by targeting the brain’s glutamate system to restore neural connections.

To monitor his brain activity, Johnson used his self-invented Kernel Flow—a form of non-invasive brain interface technology worn on the head.

S brain activity followed fixed, predictable patterns. After, he found his once-rigid thinking to be more flexible, varied, and open to new beliefs or ways of thinking. + Johnson likened his brain on ketamine to a global air traffic network, where each airport—or brain region—has consistent flight routes and traffic volumes.

“After ketamine, my brain’s activity patterns were completely scrambled. Instead of predictable routes between major hubs, traffic was rerouted to smaller, less-used airports across the U.S., Europe, and Asia,” he said in a tweet.

Continue reading “Biohacker Takes Ketamine and Tracks His Brain With Surprising Results” | >

Curing Cancer In A Flash — Dr. Bill Loo, Jr., MD, PhD — Professor, Stanford Medicine / Co-Founder, TibaRay Inc

Dr. Billy W. Loo Jr., MD PhD (https://med.stanford.edu/profiles/6839) is a Professor of Radiation Oncology, a member of the Stanford Cancer Institute, the Molecular Imaging Program at Stanford (MIPS), and of Bio-X Interdisciplinary Biosciences Institute. He is a physician-scientist Radiation Oncologist and Bioengineer who directs the Thoracic Radiation Oncology Program and is Principal Investigator of the FLASH Sciences Lab at Stanford (https://med.stanford.edu/loo-lab.html).

Dr. Loo’s clinical specialty is precision targeted radiotherapy for lung/thoracic cancers, including stereotactic ablative radiotherapy (SABR). Dr. Loo is a recognized expert in thoracic cancers serving on multiple national committees (including as writing member or vice-chair) that publish clinical guidelines on the treatment of lung cancer and other thoracic malignancies, particularly the National Comprehensive Cancer Network (NCCN).

Dr. Loo’s clinical research is in clinical trials and implementation of new treatment techniques for lung cancer, and development of new medical imaging methods for measuring organ function and predicting response to cancer treatment. He also has developed novel applications of SABR including treatment of pulmonary emphysema and cardiac arrhythmias.

The research focus of the FLASH Sciences Lab at Stanford, directed by Dr. Loo, is the development and study of extremely rapid FLASH therapy to optimize the biological therapeutic index of cancer radiotherapy, and the technological infrastructure for this basic research and its clinical translation.

Continue reading “Dr. Billy W. Loo Jr., MD PhD — Stanford Medicine / TibaRay — Curing Cancer In A Flash” | >

A team of scientists from Nanyang Technological University, Singapore (NTU Singapore) has developed an artificial ‘worm gut’ to break down plastics, offering hope for a nature-inspired method to tackle the global plastic pollution problem.

By feeding worms with plastics and cultivating microbes found in their guts, researchers from NTU’s School of Civil and Environmental Engineering (CEE) and Singapore Centre for Environmental Life Sciences Engineering (SCELSE) have demonstrated a new method to accelerate plastic biodegradation.

Previous studies have shown that Zophobas atratus worms – the larvae of the darkling beetle commonly sold as pet food and known as ‘superworms’ for their nutritional value – can survive on a diet of plastic because its gut contains bacteria capable of breaking down common types of plastic. However, their use in plastics processing has been impractical due to the slow rate of feeding and worm maintenance.

Read more | >

Imagine being able to speed up evolution – hypothetically – to learn which genes might have a harmful or beneficial effect on human health. Imagine, further, being able to rapidly generate new genetic sequences that could help cure disease or solve environmental challenges.

Now, scientists have developed a generative AI tool that can predict the form and function of proteins coded in the DNA of all domains of life, identify molecules that could be useful for bioengineering and medicine, and allow labs to run dozens of other standard experiments with a virtual query – in minutes or hours instead of years (or millennia).

Trained on a dataset that includes all known living species – and a few extinct ones – Evo 2 can predict the form and function of proteins in the DNA of all domains of life.

Read more | >

Humans have been selectively breeding cats and dogs for thousands of years to make more desirable pets. A new startup called the Los Angeles Project aims to speed up that process with genetic engineering to make glow-in-the-dark rabbits, hypoallergenic cats and dogs, and possibly, one day, actual unicorns.

The Los Angeles Project is the brainchild of biohacker Josie Zayner, who in 2017 publicly injected herself with the gene-editing tool Crispr during a conference in San Francisco and livestreamed it. “I want to help humans genetically modify themselves,” she said at the time. She’s also given herself a fecal transplant and a DIY Covid vaccine and is the founder and CEO of The Odin, a company that sells home genetic-engineering kits.

Now, Zayner wants to create the next generation of pets. “I think, as a human species, it’s kind of our moral prerogative to level up animals,” she says.

Read more | >

“Our findings suggest that senescent cells maintain their large size through improved adhesion to the extracellular matrix via AP2A1 and integrin β1 movement along enlarged stress fibers,” Chantachotikul said.

The link between AP2A1 and senescent cells, the researchers said, means the protein has the potential to be used as a marker for cellular aging.

The team also believes that the findings may offer a new target for future treatments of age-related diseases.

Read more | >

Health, vitality and longevity through bioengineering — kevin caldwell — CEO, ossium health.

Kevin Caldwell is CEO, Co-Founder & President of Ossium Health (https://ossiumhealth.com/), a commercial stage bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects.

Mr. Caldwell built Ossium from a small startup into the clinical stage bioengineering company it is today, setting the company’s mission to improve human health through bioengineering and designed its platform-based model for cellular therapeutics development. He has led the company’s successful pursuit, negotiation, and execution of more than 50 business relationships, including 5 successful fundraisings and dozens of supply partnerships, clinical partnerships, and commercial contracts with biopharmaceutical companies.

After seven years of strategic engagement and networking, Mr. Caldwell drove the team to successfully secure a transformative federal contract with BARDA (Biomedical Advanced Research and Development Authority) that validates Ossium’s innovative approach. This milestone represents the culmination of persistent relationship-building, targeted proposals, and unwavering commitment to addressing national biomedical challenges through cutting-edge technology and collaborative partnerships.

Prior to founding Ossium, Mr. Caldwell served as an Engagement Manager at McKinsey’s San Francisco office where he advised clients in the biotechnology and healthcare sectors. His projects ranged from due diligence of acquisition targets in the biotech startup ecosystem to restructuring distressed biopharma companies. Mr. Caldwell led more than 20 engagements with more than a dozen clients, leading teams that advised clients on revenue growth, go to market strategy, and organizational restructuring.

Continue reading “Kevin Caldwell — CEO, Ossium Health — Health, Vitality And Longevity Through Bioengineering” | >

Cells have surface receptors called integrins that bind to repetitive domains present on the extracellular matrix (ECM) surrounding the cells, allowing them to grow and spread. A new study from the Department of Bioengineering (BE), Indian Institute of Science (IISc) and collaborators shows that tweaking the spacing between these binding domains on the ECM can boost the efficiency of ultrasound treatment applied to kill cancer cells.

“In a normal tissue, the spacing on the ECM is around 50–70 nanometers (nm), but in the , severe choking occurs due to excessive ECM secretion, which may reduce the binding spacing to below 50 nm,” explains Ajay Tijore, Assistant Professor in BE and corresponding author of a related study published in Nano Letters. “We found more being killed when the binding spacing is increased to around 50–70 nm.”

Low-frequency ultrasound waves (39 kHz) can disrupt the and trigger cell death in cancer cells. It is a relatively low-cost and non-invasive approach. Unlike normal cells, cancer cells do not have repair mechanisms that help them withstand the exerted by ultrasound waves.

Read more | >

Mammoth Biosciences researchers have developed NanoCas, an ultracompact CRISPR nuclease, demonstrating its ability to perform gene editing in non-liver tissues, including skeletal muscle, using a single adeno-associated virus (AAV) vector. Experiments in non-human primates (NHPs) resulted in editing efficiencies exceeding 30% in muscle tissues.

CRISPR gene editing has revolutionized genetics, but delivery challenges have restricted its clinical applications primarily to ex vivo and liver-directed therapies. Conventional CRISPR nucleases, including Cas9 and Cas12a, exceed the packaging limits of a single AAV vector, necessitating dual-AAV strategies that reduce efficiency.

Smaller CRISPR systems such as Cas12i and CasX have been identified, but they remain too large or exhibit low editing efficiency. Existing compact systems like Cas14 and IscB have not demonstrated robust efficacy in large animal models.

Read more | >